VISEN PHARMA-B (02561) core product approved for commercialization, achieving revenue of 34.542 million yuan in the first half of the year.

VISEN PHARMA-B (02561) announced its interim results for 2026, achieving revenue of 34.542 million yuan and a gross profit of 18.062 million yuan. Research and development costs amounted to 37.374 million yuan, a year-on-year decrease of 19.83%. The loss for the period was approximately 104 million yuan, a year-on-year narrowing of 11.79%. The injectable lonapegsomatropin (Chinese trade name: ; English trade name: SKYTROFA) was approved by the National Medical Products Administration on January 26, 2026, marking the company's official transition to a commercial stage. During the reporting period, the company fully initiated the commercialization of lonapegsomatropin and achieved substantial progress in product supply, channel development, commercialization coverage, physician interaction, and patient support. The announcement states that the revenue was primarily due to the initial commercialization of the core product, injectable lonapegsomatropin (Chinese trade name: and English trade name: SKYTROFA). The decrease in research and development costs was mainly due to the completion of the import BLA registration for the core product lonapegsomatropin, as well as the completion of major clinical activities for palopegteriparatide and navepegritide.